Roche (Switzerland)

PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures

We developed a high-content screening to investigate how Alzheimer’s disease (AD) genetic risk factors may affect synaptic mechanisms in rat primary neuronal cultures. Of the target genes identified, we found that Plcg2 downregulation in mouse dentate gyrus neurons consistently d...

Ontogenically distinct mouse alveolar macrophages modulate cigarette smoke-induced lung inflammation via Spp1

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death. While airway-recruited macrophages contribute to COPD pathogenesis, the role of embryonic alveolar macrophages (Em-AM) remains unclear. Using a cigarette smoke (CS)-induced COPD mouse model, we find...

Quantitative biochemical profiling of GCase activity and α-synuclein proteoforms in post-mortem human brains from GBA-related and idiopathic Parkinson’s disease

Variants in GBA1 , encoding lysosomal glucocerebrosidase (GCase), are risk factors for Parkinson’s disease (PD), which is characterized by α-synuclein (αSyn) accumulation and lysosomal dysfunction. Nonetheless, the relationship between αSyn accumulation and GCase deficiency remai...

Burden, perception of stigma, and gender differences among informal care partners of individuals with mild cognitive impairment

Background Caring for individuals with mild cognitive impairment (MCI) is increasingly recognized as a significant clinical challenge. However, the latent burden, driven by perceived stigma and gender-specific vulnerabilities, remains poorly characterized during these early stage...

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis

Importance: Capturing individual multiple sclerosis (MS) progression is difficult; few studies have evaluated glial fibrillary acidic protein (GFAP) in large longitudinal cohorts with independent validation. Objective: To investigate whether serum GFAP levels and treatment-relate...

Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients with Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial

Objectives The REGENCY trial ( NCT04221477 ) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). These exploratory analyses aimed to...